The two numbers everyone is quoting
A 12-week randomized, double-blind trial published in Nutrients in May compared red sage extract — Salvia miltiorrhiza, sold as SAGX — against saw palmetto in men with lower urinary tract symptoms.
Red sage dropped International Prostate Symptom Scores by 4.6 points. Saw palmetto dropped them by 0.6.
The supplement trade press picked it up on June 2. The consumer version of this story hasn’t reached your feed yet, but it is coming, and it will arrive shaped like an advertisement. The message will be simple: switch bottles.
Before you do, I want to walk through the study properly. This is not an attack on a plant, and nobody reading this should stop anything today. But there are two numbers missing from every version of this story, and a third one that got buried.
The third number
The trial had 30 men and no placebo group.
That matters more than it sounds. In the CAMUS trial — a much larger study in the same condition — the placebo group improved 2.99 points on its own. Not the treatment group. The group that got nothing.
Urinary symptoms fluctuate. Men enroll in trials when things are bad, which means the next twelve weeks are likely to look better regardless of what they swallow. Add the effect of being watched by researchers, add regression to the mean, and you get a placebo response in this condition that is substantial and well documented.
Without a placebo arm, there is no way to separate any of that from the extract. So when you hear 4.6, hold it against the roughly 3 points that placebo alone produced in a trial ten times the size.
The fourth number
There is a concept in this literature called the minimal important difference — the amount a symptom score has to move before a man reliably notices the change in his own life. Not statistically. Actually.
The long-standing figure was around 3.1 points. But a 2025 patient-anchored analysis put it at 5.26 points overall, with a 95% confidence interval of 4.38 to 6.13. Broken out, it was 4.00 for men with moderate baseline symptoms and 8.23 for men with severe symptoms.
The winning result was 4.6.
It clears the old threshold. It does not clear the new one. Which means the headline number sits inside the zone where a man may not reliably feel the difference on a Tuesday — and that is a very different claim than the one being sold.
The number that got buried
Now the part I actually care about: 0.6.
Saw palmetto is the most commonly self-prescribed prostate product in North America. And that 0.6 is the third time it has been fairly tested and come up empty.
STEP, New England Journal of Medicine, 2006. 225 men with moderate-to-severe symptoms, 160 mg twice daily, for a full twelve months. No advantage over placebo on symptom score, peak urinary flow, post-void residual volume, prostate size, or quality of life.
CAMUS, JAMA, 2011. This one escalated the dose — 320 mg a day, then 640, then 960, twenty-four weeks at each level. Symptom scores fell 2.20 points on saw palmetto and 2.99 points on placebo. The placebo group did numerically better. No benefit at any dose, and no benefit across a range of secondary outcomes including nighttime urination, peak flow and residual volume.
2026. 0.6 points.
This is not a scandal. This is what fair testing looks like. A plant extract got a serious hearing, repeatedly, in top-tier journals, and it did not outperform placebo.
And if you took saw palmetto for a year and felt nothing — that was not you being inconsistent. That was the finding.
One fair caveat, because it deserves stating: these trials tested specific standardized extracts at specific doses. Someone can always argue a different preparation might behave differently. That argument has been available for twenty years and has not yet been backed by a comparably rigorous trial.
What “better than saw palmetto” actually means
Here is the sentence nobody will print. Saw palmetto has repeatedly failed to beat placebo. So beating saw palmetto is much closer to beating nothing than the coverage implies.
To be straight about red sage: the evidence is weak, not absent. Alongside the 30-man pilot there is a 136-man multicenter, randomized, double-blind, placebo-controlled trial in which red sage did beat placebo across emptying, frequency, intermittency, weak stream, urgency, nighttime urination and quality of life, with no serious adverse events causing discontinuation. That is a real study and it deserves to be counted.
It is also one moderate trial. Ask me again in three years.
And a safety note, because it isn’t in the marketing: Salvia miltiorrhiza has anticoagulant-relevant properties. Any man on blood thinners, aspirin therapy, or blood pressure medication talks to a pharmacist before touching it. The trials did not study those interactions.
What the prostate is actually sitting in
Now the part that changes what you do tomorrow.
Metabolic syndrome is present in somewhere between 26.5% and 55.6% of men with lower urinary tract symptoms across international studies. That is not a footnote. That is a quarter to more than half of the men in this conversation.
And the proposed mechanisms are specific rather than hand-waving:
- Sympathetic nervous system overactivity, keeping smooth muscle tight
- Chronic inflammation driven by high blood glucose and high insulin
- High insulin lowering sex hormone-binding globulin, which changes how much sex hormone reaches prostate cells
- Impaired nitrergic signalling — degraded nitric oxide function in the tissue itself
- Increased Rho-kinase activity, affecting smooth muscle tone
Newer single-cell research is pushing the same direction, reframing prostate enlargement as substantially an inflammatory and fibrotic process rather than a purely androgen-driven one. I’ll state the limit plainly: that is a mechanism map, not a treatment. Nobody has run the trial showing that fixing your metabolic picture changes prostate size.
But look at that fourth mechanism again. Nitric oxide signalling. That is the same pathway that governs erectile response.
The bathroom and the bedroom are not two problems. The prostate is not failing in isolation. It sits inside the same vascular and metabolic environment that runs your erections, your energy and your sleep. That has consequences.
Why the bottle wins anyway
Here is the honest psychology, and I say it with respect because it is completely reasonable.
A supplement is the only intervention for this problem that requires telling nobody. No appointment. No exam. No conversation with your wife about why you’re seeing a urologist. It is private, and privacy is the actual product.
So when a study says the private option didn’t work, the instinct is to buy the next private option. Same shelf, same drawer, same 3 a.m. — but now you believe you’re handling it.
That belief costs more than the supplement did. It buys another year of not checking four numbers.
What to do instead — with the grades attached
Four numbers, inside thirty days. Blood pressure, measured at home, sitting, twice a week at the same time of day. Fasting glucose or A1c. Waist measured at the navel, not your pant size. And an honest answer about sleep — if you snore, wake unrefreshed, or your partner has ever mentioned that you stop breathing, that is a sleep evaluation, not a supplement question.
Movement, and I’ll give you the honest grade. In PLCO data covering more than 28,000 men with prostate enlargement, men who were physically active at least an hour a week were 13% less likely to report nighttime urination and 34% less likely to report severe nighttime urination. That is a cohort study. Association, not proof.
And a randomized controlled trial of weight reduction in men with these symptoms came back null — no significant difference in symptom score, nighttime urination, quality of life or flow measures.
I’m telling you both, because you should hear the weak results from me and not from someone in the comments.
So why do I still tell you to train? Because three resistance sessions and daily walking pay out in blood pressure, insulin sensitivity and vascular function whether or not they change your stream. The downside is zero and the collateral return is large. A supplement’s collateral return is zero. That asymmetry is the whole argument, and it survives the disclosure.
Food, as nutritional support and nothing more. Nitrate-rich vegetables — beets, arugula, spinach — for the nitric oxide pathway. Tomatoes cooked with a fat source, and cruciferous vegetables, for prostate-health nutrition. Fatty fish for omega-3s. Pumpkin seeds and oysters for zinc. This is food. It is not medicine and I’m not going to pretend otherwise.
Fluid timing. Front-load fluid earlier in the day, taper in the last three hours before bed, and be honest about alcohol and late caffeine.
The question for your doctor. Not “should I take saw palmetto.” Ask this:
“Given my blood pressure, my glucose and my waist, how much of my urinary symptom picture do you think is metabolic — and what would you want to see change first?”
That question gets you a different appointment than the one you were going to have.
The close
You are not going to supplement your way out of a vascular and metabolic problem.
You’re going to measure four numbers. Move three times a week. Fix your sleep if it’s broken. And have a better conversation with your doctor than the one you were planning to have.
Stop with the excuses. Let’s get healthy.
Want the food side of this? Three starter recipes built around nitrate-rich ingredients are in a free PDF — The 3-Glass Blood Flow Starter.
This article is for informational and educational purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Consult a healthcare professional before making changes to your diet or before starting or stopping any supplement or nutritional routine, especially if you have a medical condition or take prescription medications.